Search

Your search keyword '"Christoph Mamot"' showing total 4 results
Start Over Author "Christoph Mamot" Journal hematological oncology
4 results on '"Christoph Mamot"'

1. DEVELOPMENT AND VALIDATION OF A PET RADIOMICS PROGNOSTIC MODEL FOR DIFFUSE LARGE B CELL LYMPHOMA

Author

Luciano Cascione, Stefan Dirnhofer, Andrea Bruno, Luca Giovanella, F. Esposito, Giuseppe Gritti, Federico Dalmasso, Lisa Milan, Alessandro Rambaldi, S. Chauvie, Christoph Mamot, Stefanie Hayoz, Emanuele Zucca, Säm Schär, and Luca Ceriani

Subjects
Cancer Research, Oncology, Radiomics, business.industry, Prognostic model, Cancer research, Medicine, Hematology, General Medicine, business, medicine.disease, Diffuse large B-cell lymphoma
Published
2021

2. INTEGRATION OF BASELINE METABOLIC PARAMETERS AND MUTATIONAL PROFILE PREDICTS OUTCOME IN DLBCL PATIENTS. A POST HOC ANALYSIS OF SAKK38/07 STUDY

Author

Alexandar Tzankov, Luca Giovanella, Emanuele Zucca, Luca Ceriani, Stefan Dirnhofer, G Ghilardi, S Genta, Sämi Schär, Stefanie Hayoz, Darius Juskevicius, Christoph Mamot, and Luciano Cascione

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Internal medicine, Post-hoc analysis, Medicine, Hematology, General Medicine, Baseline (configuration management), business, Outcome (game theory)
Published
2021

3. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT

Author

Luca Mazzucchelli, Stefanie Hayoz, L. Giovannella, Anastasios Stathis, Alden A. Moccia, Christoph Mamot, S. Ferrari, Andrea Bruno, Stefan Dirnhofer, Emanuele Zucca, Luca Ceriani, Maria Cristina Pirosa, Giuseppe Gritti, Alessandro Rambaldi, and Teresa Ruberto

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Metabolic heterogeneity, business.industry, Hematology, General Medicine, medicine.disease, Outcome (game theory), Lymphoma, Internal medicine, Cohort, Medicine, Tumour volume, business
Published
2019

4. DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL-B

Author

Urban Novak, David R. Westhead, Thomas Cummin, Michael A. Bentley, Christopher Pocock, Reuben Tooze, Tom Maishman, S. Barrans, Michael Wang, Debbie Hamid, Matthew A. Care, Alexandra Clipson, Paul Fields, Andrew McMillan, Chulin Sha, Peter Johnson, Andrew Jack, Andrew Davies, Shamim Kazmi-Stokes, Graham P. Collins, Anton Kruger, Joshua Caddy, Gareth Griffiths, Ming-Qing Du, C. Burton, and Christoph Mamot

Subjects
Cancer Research, Pathology, medicine.medical_specialty, Bortezomib, Germinal center, Hematology, General Medicine, Biology, medicine.disease, Phenotype, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Gene expression, medicine, Transcriptome profiling, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug
Abstract

DLBL subtypes identified by patterns of gene expression correspond to germinal center (GCB) or activated (ABC) B‐cells like. The latter demonstrate dysregulation of the NF‐KB pathway. Outcomes of treatment with R‐CHOP are inferior for ABC DLBL in retrospective series. This study investigated whether adding bortezomib (B), a putative NF‐KB inhibitor, can reverse this phenotype.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results